Pfizer jumps on early data from BioNTech-partnered COVID-19 vaccine study

Marco Green
July 3, 2020

Data from BNT162b1 comes from the first part of the study, which included 45 healthy adults aged 18 to 55.

It said the higher of the two doses - both administered via two injections within three weeks of one another - was followed by a short fever in three out of four participants after the second shot. "Virus neutralizing antibody titers achieved after two doses are greater than convalescent antibody titers", tweeted Peter Hotez, a vaccine scientist from Baylor College of Medicine in the USA, who was unrelated to the study. Higher antibody levels in patients who'd received the vaccine are a useful proxy for immunity to covid-19, but we don't yet know for sure that they guarantee immunity.

No COVID-19 vaccine has yet been approved for commercial use.

"We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings", said Kathrin U. Jansen, study co-author and Senior Vice President and Head of Vaccine Research & Development, Pfizer.

"These first trial results show that the vaccine yields immune activity and causes a strong immune response", said BioNTech's co-founder and Chief Executive Officer Ugur Sahin.

The FTSE 100 has rebounded sharply since a coronavirus-driven crash in March, but is still down about 17% on the year with investors closely tracking reports of a resurgence in COVID-19 cases, which could lead to another shutdown. "We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible", she added.

Oil prices edged higher Thursday after Energy Information Administration data late Wednesday showed USA crude inventories fell 7.2 million barrels from a record high last week, far more than expected.

The big headline-grabber from the results was the fact that all patients who received either the 10 or 30 microgram doses, (interestingly not the other 100mg dose) in a 28 day period developed virus-neutralizing antibodies.

Other reports by Click Lancashire

Discuss This Article